Purchase this article with an account.
Y. Ebihara, A. Mekada, M. Tajika, Y. Takihata, E. Sekii, A. Okada, M. Ohji; Intravitreal Injection of Triamcinolone Acetonide for the Treatment of Macula Edema Due to Branch Retinal Vein Occlusion . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4264.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and safety of intravitreal injection of triamcinolone acetonide (TA) to treat macula edema secondary to branch retinal vein occlusion (BRVO).
Twenty–five eyes of 25 consecutive BRVO patients with macula edema with best–corrected visual acuity (BCVA) of 20/30 or less were included. The patients received one 4–mg intravitreal injection of TA. The BCVA and intraocular pressure (IOP) were assessed at baseline and at 1, 3, and 6 months after the TA injection.
The mean logMAR visual acuity level was 0.60±0.45 at baseline and improved significantly to 0.28±0.37 at 1 month (p<0.01), 0.29±0.32 at 3 months (p<0.01), and 0.26±0.32 at 6 months (p<0.01). The BCVA improved by 3 lines or more in 14 patients (56%); no patient lost 3 or more lines of BCVA at 6 months. The IOP increased by greater than 10 mmHg compared with baseline in 4 patients (16%). No serious adverse effects developed.
Intravitreal injection of TA achieved a significant improvement of BCVA in patients with macula edema secondary to BRVO for the short term after the injection. TA seems to be a safe and effective treatment for BRVO. Further follow–up is required to determine if macula edema recurs after the treatment of BRVO.
This PDF is available to Subscribers Only